IHE participates at Virtual ISPOR Europe 2020

IHE participates at the virtual conference next week with two posters.

Name of Conference: Virtual ISPOR Europe 2020
Date: November 16-19, 2020

A study on quality of life in phenylketonuria (PKU) using time trade off and discrete choice will be presented.

Title: The Impact on Quality of Life of Diet Restrictions and Disease Symptoms Associated with Phenylketonuria in Sweden

Name of authors: Paul Okhuoya, Sara Olofsson, Katarina Gralén, Ulf Persson, Jennifer Quinn, Christina Hoxer

Name of Presenter: Paul Okhuoya

The second poster presentation looking at the cost-effectiveness of canagliflozin added to standard of care for treating DKD in patients with type 2 diabetes in England.

Cost-effectiveness of canagliflozin added to standard of care (SoC) was evaluated using a newly developed microsimulation model (CREDEM-DKD) based on the CREDENCE trial.

Canagliflozin plus SoC was associated with gains in life-years and QALYs versus SoC over 40 years, driven largely by reductions in the rates of dialysis start and HHF, MI, and stroke events. Substantial cost offsets for dialysis and transplant lead to cost savings for canagliflozin.

Extrapolating the CREDENCE trial over 40 years suggests that canagliflozin can substantially reduce rates of renal and cardiovascular outcomes, increase longevity, and save costs in this high unmet need population.

Title: Use of a New Discrete Event Simulation Model to Predict the Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes in England

Name of authors: Ball P, Willis M, Nilsson A, Traina S, Roe R, Kellerborg K

Name of Presenter: Ball P